Advertisement

CNS Drugs

, Volume 23, Issue 4, pp 281–292 | Cite as

Suicidality in People Taking Antiepileptic Drugs

What is the Evidence?
Leading Article

Abstract

Suicide is an important cause of premature death. In the general population, most people who commit suicide have a psychiatric problem at the time. People with epilepsy are thought to be at increased risk from suicide and suicidality (suicidal ideation or behaviour). Standardized mortality ratios estimated for suicide in people with epilepsy are usually between 3 and 5. Risk factors for suicide in people with epilepsy have been suggested, including early age of onset of seizures, temporal lobe epilepsy, severe seizures and recent control of seizures. Psychiatric co-morbidity also seems to be an important factor in people with epilepsy who commit suicide.

In recent years, suicidality has been recognized as a complication of several groups of drugs and, most recently, antiepileptic drugs (AEDs) have been implicated. The US FDA performed a meta-analysis of 199 placebo-controlled studies of 11 AEDs used for seizure control, psychiatric or ‘other’ indications. There were four completed suicides in those taking AEDs and none in those taking placebo. The odds ratio for suicidal behaviour or ideation was 1.8 (95% CI 1.24, 2.66), suggesting that people taking AEDs are more at risk than those taking placebo. The odds ratio was significantly raised for people taking AEDs for epilepsy, but not for the other indications.

AEDs may affect mood by means of several mechanisms. In people with epilepsy, however, the concept of forced normalization (or alternative psychosis) may also play a part. In this situation, control of seizures (by AEDs or epilepsy surgery) may alternate with psychotic features or, less commonly, depression, although this is not fully understood.

The risk of suicidal ideation and behaviour as adverse effects of AED treatment, although increased, seems low. As a result of the FDA’s alert clinicians are supposed to inform patients and their families of this increased risk but it is important to place it in a proper perspective. Some people with epilepsy are more likely to develop psychiatric adverse effects with any AEDs, and these people should be followed closely whenever a new AED is introduced. Nonetheless, in people with epilepsy the risk of suicidality associated with AEDs needs to be balanced against the risk of not treating the seizures. In fact, the risk of stopping AEDs or refusing to start AEDs for the control of a seizure disorder may be significantly worse and may result in serious harm, including death of the patient

Keywords

Suicidal Ideation Suicide Attempt Lamotrigine Topiramate Suicidal Behaviour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This work was supported by the UK National Society for Epilepsy and by UCLH/UCL, which receives a proportion of funding from the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centers funding scheme.

The authors received no funding for the present paper. Dr Sander and Dr Mula have received travel grants or consultancy fees from various pharmaceutical companies, including Novartis, Pfizer, UCB Pharma, Eisai, Schwarz Pharma, Janssen-Cilag, sanofi-aventis and GlaxoSmith-Kline, which are involved in the manufacture of antiepileptic drugs. Dr Bell has no conflicts of interest that are directly relevant to the current review.

References

  1. 1.
    World Health Organization. WHO statistical information service [online]. Available from URL: http://www.who.int. [Accessed 2008 May 16]
  2. 2.
    Gelder MG, Lopez-Ibor JJ, Andreasen N, editors. New Oxford textbook of psychiatry. Oxford: Oxford University Press, 2003Google Scholar
  3. 3.
    National Center for Injury Prevention and Control. Centers of disease control and prevention (CDC): web-based injury statistics query and reporting system [online]. Available from URL: http://www.cdc.gov/ncipc/wisqars/default.htm.2008. [Accessed 2008 May 23]
  4. 4.
    Murray CJL, Lopez AD, Mathers CD et al. The global burden of disease 2000 project: aims, methods and data sources [online]. Available from URL: http://www.who.int/healthinfo/paper36.pdf. 2001. [Accessed 2007 Jan 16]
  5. 5.
    Barraclough B, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974 Oct; 125: 355–73PubMedCrossRefGoogle Scholar
  6. 6.
    Blumenthal SJ, Kupfer DJ. Generalizable treatment strategies for suicidal behavior. Ann N Y Acad Sci 1986; 487: 327–40PubMedCrossRefGoogle Scholar
  7. 7.
    Blumenthal S, Kupfer D. Overview of early detection and treatment strategies for suicidal behavior in young people. J Youth Adolesc 1988; 17(1): 1–23CrossRefGoogle Scholar
  8. 8.
    Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997 Mar; 170: 205–28PubMedCrossRefGoogle Scholar
  9. 9.
    Kovacs M, Goldston D, Gatsonis C. Suicidal behaviors and childhood-onset depressive disorders: a longitudinal investigation. J Am Acad Child Adolesc Psychiatry 1993; 32(1): 8–20PubMedCrossRefGoogle Scholar
  10. 10.
    Brezo J, Paris J, Hebert M, et al. Broad and narrow personality traits as markers of one-time and repeated suicide attempts: a population-based study. BMC Psychiatry 2008; 8: 15PubMedCrossRefGoogle Scholar
  11. 11.
    Morgan HG, Stanton R. Suicide among psychiatric in-patients in a changing clinical scene: suicidal ideation as a paramount index of short-term risk. Br J Psychiatry 1997 Dec; 171: 561–3PubMedCrossRefGoogle Scholar
  12. 12.
    Shah AK, Ganesvaran T. Inpatient suicides in an Australian mental hospital. Aust NZ J Psychiatry 1997 Apr; 31(2): 291–8CrossRefGoogle Scholar
  13. 13.
    Brown GK, Beck AT, Steer RA, et al. Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. J Consult Clin Psychol 2000 Jun; 68(3): 371–7PubMedCrossRefGoogle Scholar
  14. 14.
    Shen X, Hackworth J, McCabe H, et al. Characteristics of suicide from 1998–2001 in metropolitan area. Death Stud 2006 Nov; 30(9): 859–71PubMedCrossRefGoogle Scholar
  15. 15.
    Snowdon J, Baume P. A study of suicides of older people in Sydney. Int J Geriatr Psychiatry 2002 Mar; 17(3): 261–9PubMedCrossRefGoogle Scholar
  16. 16.
    Nordentoft M. Prevention of suicide and attempted suicide in Denmark: epidemiological studies of suicide and intervention studies in selected risk groups. Dan Med Bull 2007; 54(4): 306–69PubMedGoogle Scholar
  17. 17.
    Lhatoo SD, Johnson AL, Goodridge DM, et al. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol 2001 Mar; 49(3): 336–44PubMedCrossRefGoogle Scholar
  18. 18.
    Hitiris N, Mohanraj R, Norrie J, et al. Mortality in epilepsy. Epilepsy Behav 2007 May; 10: 363–76PubMedCrossRefGoogle Scholar
  19. 19.
    Nilsson L, Tomson T, Farahmand BY, et al. Cause-specific mortality in epilepsy: a cohort study of more than 9000 patients once hospitalized for epilepsy. Epilepsia 1997 Oct; 38(10): 1062–8PubMedCrossRefGoogle Scholar
  20. 20.
    Christensen J, Vestergaard M, Mortensen PB, et al. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007 Aug; 6(8): 693–8PubMedCrossRefGoogle Scholar
  21. 21.
    Robertson MM. Suicide, parasuicide, and epilepsy. In: Engel J, Pedley T, editors. Epilepsy: a comprehensive textbook. Philadelphia (PA): Lippincott-Raven, 1997: 2141–51Google Scholar
  22. 22.
    Chapell R, Reston, J, Snyder, D. Management of treatment-resistant epilepsy: evidence report/technology assessment no. 77 (prepared by the ECRI evidence-based practice center under contract no. 290-97-0020) Rockville (MD): Agency for Healthcare Research and Quality, 2003. AHRQ publication no. 03-0028Google Scholar
  23. 23.
    Nilsson L, Ahlbom A, Farahmand BY, et al. Risk factors for suicide in epilepsy: a case control study. Epilepsia 2002 Jun; 43(6): 644–51PubMedCrossRefGoogle Scholar
  24. 24.
    Blumer D, Montouris G, Davies K, et al. Suicide in epilepsy: psychopathology, pathogenesis, and prevention. Epilepsy Behav 2002 Jun; 3(3): 232–41PubMedCrossRefGoogle Scholar
  25. 25.
    Kalinin VV, Polyanskiy DA. Gender differences in risk factors of suicidal behavior in epilepsy. Epilepsy Behav 2005 May; 6(3): 424–9PubMedCrossRefGoogle Scholar
  26. 26.
    Mendez MF, Lanska DJ, Manon-Espaillat R, et al. Causative factors for suicide attempts by overdose in epileptics. Arch Neurol 1989 Oct; 46(10): 1065–8PubMedCrossRefGoogle Scholar
  27. 27.
    O’Donnell J, Bateman DN. Lamotrigine overdose in an adult. J Toxicol Clin Toxicol 2000; 38(6): 659–60PubMedCrossRefGoogle Scholar
  28. 28.
    Fukuchi T, Kanemoto K, Kato M, et al. Death in epilepsy with special attention to suicide cases. Epilepsy Res 2002 Oct; 51(3): 233–6PubMedCrossRefGoogle Scholar
  29. 29.
    Brent DA. Overrepresentation of epileptics in a consecutive series of suicide attempters seen at a children’s hospital, 1978–1983. J Am Acad Child Psychiatry 1986 Mar; 25(2): 242–6PubMedCrossRefGoogle Scholar
  30. 30.
    Caplan R, Siddarth P, Gurbani S, et al. Depression and anxiety disorders in pediatric epilepsy. Epilepsia 2005 May; 46(5): 720–30PubMedCrossRefGoogle Scholar
  31. 31.
    Ott D, Siddarth P, Gurbani S, et al. Behavioral disorders in pediatric epilepsy: unmet psychiatric need. Epilepsia 2003 Apr; 44(4): 591–7PubMedCrossRefGoogle Scholar
  32. 32.
    UK Committee on Safety of Medicines. Seroxat must not be used for treatment of children. 2003 [online]. Available from URL: http://www.mhra.gov.uk/home/groups/commspo/documents/news/con002035.pdf [Accessed 2008 Jun 3]
  33. 33.
    US Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant. 2004 [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm [Accessed 2008 Jun 3]
  34. 34.
    Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292(3): 338–43PubMedCrossRefGoogle Scholar
  35. 35.
    Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007 Jul; 164(7): 1029–34PubMedCrossRefGoogle Scholar
  36. 36.
    Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry 2006 Jan; 163(1): 41–7PubMedCrossRefGoogle Scholar
  37. 37.
    Joint Formulary Committee. British national formulary [online]. Available from URL: http://www.bnf.org.uk [Accessed 2008 Jun 3]
  38. 38.
    Reith DM, Edmonds L. Assessing the role of drugs in suicidal ideation and suicidality. CNS Drugs 2007; 21(6): 463–72PubMedCrossRefGoogle Scholar
  39. 39.
    US Food and Drug Administration. Antiepileptic drugs and suicidality. 23-5-2008 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf [Accessed 2008 Jun 30]
  40. 40.
    Katz R. FDA update. Epilepsy Res 2006 Jan; 68(1): 85–94PubMedCrossRefGoogle Scholar
  41. 41.
    Seethalakshmi R, Krishnamoorthy ES. Depression in epilepsy: phenomenology, diagnosis and management. Epileptic Disord 2007 Mar; 9(1): 1–10PubMedGoogle Scholar
  42. 42.
    Gilliam F. The impact of epilepsy on subjective health status. Curr Neurol Neurosci Rep 2003 Jul; 3(4): 357–62PubMedCrossRefGoogle Scholar
  43. 43.
    Harden CL, Maroof DA, Nikolov B, et al. The effect of seizure severity on quality of life in epilepsy. Epilepsy Behav 2007 Sep; 11(2): 208–11PubMedCrossRefGoogle Scholar
  44. 44.
    Turky A, Beavis JM, Thapar AK, et al. Psychopathology in children and adolescents with epilepsy: an investigation of predictive variables. Epilepsy Behav 2008 Jan; 12(1): 136–44PubMedCrossRefGoogle Scholar
  45. 45.
    Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia 1999; 40Suppl. 10: 21–47CrossRefGoogle Scholar
  46. 46.
    Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53(5 Suppl. 2): 53–67Google Scholar
  47. 47.
    Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007; 30(7): 555–67PubMedCrossRefGoogle Scholar
  48. 48.
    Trimble MR. Biological psychiatry. 2nd ed. Chichester: Wiley & Sons, 1996Google Scholar
  49. 49.
    Olajide D, Lader M. Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychol Med 1984 Nov; 14(4): 937–40PubMedCrossRefGoogle Scholar
  50. 50.
    Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995 Aug; 34(4): 275–81PubMedCrossRefGoogle Scholar
  51. 51.
    Mula M, Trimble MR, Sander JW. The role of hippo-campal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 2003 Dec; 44(12): 1573–7PubMedCrossRefGoogle Scholar
  52. 52.
    Quiske A, Helmstaedter C, Lux S, et al. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000 Apr; 39(2): 121–5PubMedCrossRefGoogle Scholar
  53. 53.
    Bremner JD, Narayan M, Anderson ER, et al. Hippo-campal volume reduction in major depression. Am J Psychiatry 2000 Jan; 157(1): 115–8PubMedGoogle Scholar
  54. 54.
    Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002 Jul; 159(7): 1112–8PubMedCrossRefGoogle Scholar
  55. 55.
    Reynolds EH. Neurological aspects of folate and vitamin B12 metabolism. Clin Haematol 1976 Oct; 5(3): 661–96PubMedGoogle Scholar
  56. 56.
    Sander JW, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992 Oct; 13(1): 89–92PubMedCrossRefGoogle Scholar
  57. 57.
    Landolt H. Serial EEG investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorenz de Haas AM, editor. Lectures on epilepsy. Amsterdam: Elsevier, 1958: 91–133Google Scholar
  58. 58.
    Trimble MR, Schmitz B. Forced normalization and alternative psychoses of epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd, 1998Google Scholar
  59. 59.
    Gibbs F. Ictal and non-ictal psychiatric disorders in temporal lobe epilepsy. J Nerv Ment Dis 1951 June; 113(6): 522–8PubMedCrossRefGoogle Scholar
  60. 60.
    Tellenbach H. Epilepsie als anfallsleiden und als psychose: uber alternative psychosen paranoider pragung bei “forcierter normalisierung” (Landolt) des elektroenzephalo-gramms epileptischer. Nervenarzt 1965 May; 36: 190–202PubMedGoogle Scholar
  61. 61.
    Krishnamoorthy ES, Trimble MR, Sander JW, et al. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy Behav 2002 Aug; 3(4): 303–8PubMedCrossRefGoogle Scholar
  62. 62.
    Seethalakshmi R, Krishnamoorthy ES. The complex relationship between seizures and behavior: an illustrative case report. Epilepsy Behav 2007 Feb; 10(1): 203–5PubMedCrossRefGoogle Scholar
  63. 63.
    Gatzonis SD, Stamboulis E, Siafakas A, et al. Acute psychosis and EEG normalisation after vagus nerve stimulation. J Neurol Neurosurg Psychiatry 2000 Aug; 69(2): 278–9PubMedCrossRefGoogle Scholar
  64. 64.
    Blumer D, Altshuler L. Affective disorders. In: Engel J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia (PA): Lippincott-Raven, 1997: 2083–99Google Scholar
  65. 65.
    Schmitz B, Trimble M. Epilogue. In: Trimble MR, Schmitz B, editors. Forced normalization the alternative psychoses of epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd, 1998: 221–7Google Scholar
  66. 66.
    Krishnamoorthy ES, Trimble MR. Forced normalization: clinical and therapeutic relevance. Epilepsia 1999; 40 Suppl. 10: 57–64CrossRefGoogle Scholar
  67. 67.
    Wolf P. Acute behavioural symptomatology at disappearance of epileptiform EEG abnormality: paradoxical or forced normalization. In: Smith D, Treiman D, Trimble MR, editors. Neurobehavioural problems in epilepsy. New York (NY): Raven Press, 1991Google Scholar
  68. 68.
    Blumer D, Davies K, Alexander A, et al. Major psychiatric disorders subsequent to treating epilepsy by vagus nerve stimulation. Epilepsy Behav 2001 Oct; 2(5): 466–72PubMedCrossRefGoogle Scholar
  69. 69.
    Mendez MF, Doss RC. Ictal and psychiatric aspects of suicide in epileptic patients. Int J Psychiatry Med 1992; 22(3): 231–7PubMedCrossRefGoogle Scholar
  70. 70.
    Ettinger AB. Psychotropic effects of antiepileptic drugs. Neurology 2006 Dec; 67(11): 1916–25PubMedCrossRefGoogle Scholar
  71. 71.
    Hirschfeld R, Bowden C, Gitlin M, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159Suppl. 4: 64–110Google Scholar
  72. 72.
    Collins JC, McFarland BH. Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord 2008 Apr; 107(1-3): 23–8PubMedCrossRefGoogle Scholar
  73. 73.
    Yerevanian BI, Koek RJ, Mintz J. Lithium, anti-convulsants and suicidal behavior in bipolar disorder. J Affect Disord 2003 Feb; 73(3): 223–8PubMedCrossRefGoogle Scholar
  74. 74.
    Cramer JA, De Rue K, Devinsky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003 Apr; 4(2): 124–32PubMedCrossRefGoogle Scholar
  75. 75.
    Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987 Dec; 80(6): 909–17PubMedGoogle Scholar
  76. 76.
    Forbes RA, Kalra H, Hackett LP, et al. Deliberate self-poisoning with tiagabine: an unusual toxidrome. Emerg Med Australas 2007 Dec; 19(6): 556–8PubMedCrossRefGoogle Scholar
  77. 77.
    Anand JS, Chodorowski Z, Wisniewski M. Seizures induced by topiramate overdose [letter]. Clin Toxicol (Phila) 2007; 45(2): 197CrossRefGoogle Scholar
  78. 78.
    Brahmi N, Kouraichi N, Abderrazek H, et al. Clinical experience with carbamazepine overdose: relationship between serum concentration and neurological severity [letter]. J Clin Psychopharmacol 2008 Apr; 28(2): 241–3PubMedCrossRefGoogle Scholar
  79. 79.
    van Opstal JM, Janknegt R, Cilissen J, et al. Severe overdosage with the antiepileptic drug oxcarbazepine. Br J Clin Pharmacol 2004 Sep; 58(3): 329–31PubMedCrossRefGoogle Scholar
  80. 80.
    Rengstorff DS, Milstone AP, Seger DL, et al. Felbamate overdose complicated by massive crystalluria and acute renal failure. J Toxicol Clin Toxicol 2000; 38(6): 667–9PubMedCrossRefGoogle Scholar
  81. 81.
    Nagel TR, Schunk JE. Felbamate overdose: a case report and discussion of a new antiepileptic drug. Pediatr Emerg Care 1995 Dec; 11(6): 369–71PubMedCrossRefGoogle Scholar
  82. 82.
    Fernandez MC, Walter FG, Petersen LR, et al. Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects. J Toxicol Clin Toxicol 1996; 34(4): 437–9PubMedCrossRefGoogle Scholar
  83. 83.
    Buckley NA, Whyte IM, Dawson AH. Self-poisoning with lamotrigine [letter]. Lancet 1993 Dec; 342(8886–8887): 1552–3PubMedCrossRefGoogle Scholar
  84. 84.
    Braga AJ, Chidley K. Self-poisoning with lamotrigine and pregabalin. Anaesthesia 2007 May; 62(5): 524–7PubMedCrossRefGoogle Scholar
  85. 85.
    Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav 2007 Aug; 11(1): 130–2PubMedCrossRefGoogle Scholar
  86. 86.
    Pompili M, Girardi P, Lester D, et al. Suicide soon after generalized tonic-clonic seizure: a possible peri-ictal phenomenon? Scientific World Journal 2006; 6: 356–60PubMedCrossRefGoogle Scholar
  87. 87.
    Barrueto Jr F, Williams K, Howland MA, et al. A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol 2002; 40(7): 881–4PubMedCrossRefGoogle Scholar
  88. 88.
    Leach JP, Stolarek I, Brodie MJ. Deliberate overdose with the novel anticonvulsant tiagabine. Seizure 1995 Jun; 4(2): 155–7PubMedCrossRefGoogle Scholar
  89. 89.
    Abraham G. Topiramate-induced suicidality [letter]. Can J Psychiatry 2003 Mar; 48(2): 127–8PubMedGoogle Scholar
  90. 90.
    Smith AG, Brauer HR, Catalano G, et al. Topiramate overdose: a case report and literature review. Epilepsy Behav 2001 Dec; 2(6): 603–7PubMedCrossRefGoogle Scholar
  91. 91.
    Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999 Oct; 53(7): 1503–11PubMedCrossRefGoogle Scholar
  92. 92.
    Mago R, Huege S, Ahuja N, et al. Zonisamide-induced suicidal ideation. Psychosomatics 2006 Jan; 47(1): 68–9PubMedCrossRefGoogle Scholar
  93. 93.
    Rubinger D, Levy M, Roll D, et al. Inefficiency of haemodialysis in acute phenytoin intoxication [letter]. Br J Clin Pharmacol 1979 Apr; 7(4): 405–7PubMedCrossRefGoogle Scholar
  94. 94.
    Blair AA, Hallpike JF, Lascelles PT, et al. Acute diphenylhydantoin and primidone poisoning treated by peritoneal dialysis. J Neurol Neurosurg Psychiatry 1968 Oct; 31(5): 520–3PubMedCrossRefGoogle Scholar
  95. 95.
    Hintze G, Klein HH, Prange H, et al. A case of valproate intoxication with excessive brain edema. Klin Wochenschr 1987 May; 65(9): 424–7PubMedCrossRefGoogle Scholar
  96. 96.
    Hawton K, Fagg J, Marsack P. Association between epilepsy and attempted suicide. J Neurol Neurosurg Psychiatry 1980 Feb; 43(2): 168–70PubMedCrossRefGoogle Scholar
  97. 97.
    Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007 Dec; 48(12): 2322–6PubMedGoogle Scholar
  98. 98.
    Gilliam FG, Santos JM. Adverse psychiatric effects of antiepileptic drugs. Epilepsy Res 2006 Jan; 68(1): 67–9PubMedCrossRefGoogle Scholar
  99. 99.
    Frank E, Cyranowski JM, Rucci P, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry 2002 Oct; 59(10): 905–11PubMedCrossRefGoogle Scholar
  100. 100.
    Mula M, Jauch R, Cavanna A, et al. Clinical and psychopathological definition of the inter-ictal dysphoric disorder of epilepsy. Epilepsia 2008 Apr; 49(4): 650–6PubMedCrossRefGoogle Scholar
  101. 101.
    Mainio A, Alamaki K, Karvonen K, et al. Depression and suicide in epileptic victims: a population-based study of suicide victims during the years 1988–2002 in northern Finland. Epilepsy Behav 2007 Nov; 11(3): 389–93PubMedCrossRefGoogle Scholar
  102. 102.
    Jones JE, Hermann BP, Barry JJ, et al. Rates and risk fators for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav 2003 Oct; 4Suppl. 3: 31–8CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Gail S. Bell
    • 1
  • Marco Mula
    • 2
  • Josemir W. Sander
    • 1
    • 3
  1. 1.Department of Clinical and Experimental EpilepsyUCL Institute of Neurology, and National Hospital for Neurology and Neurosurgery UCL Hospitals NHS Foundation TrustLondonUK
  2. 2.Department of Clinical and Experimental MedicineSection of Neurology, Amedeo Avogadro UniversityNovaraItaly
  3. 3.SEIN-Epilepsy Institutes in the Netherlands FoundationAchterweg, Heemstedethe Netherlands

Personalised recommendations